Anti-Tumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models

Androgen deprivation therapy and second-generation androgen receptor signaling inhibitors such as enzalutamide (ENZA) are standard treatments for advanced/metastatic prostate cancer. Unfortunately, most men develop resistance and relapse; signaling via insulin-like growth factor (IGF) has been impli...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular cancer therapeutics 2020-02, Vol.19 (4), p.1059-1069
Hauptverfasser:	Weyer-Czernilofsky, Ulrike, Hofmann, Marco H., Friedbichler, Katrin, Baumgartinger, Rosa, Adam, Paul J., Solca, Flavio, Kraut, Norbert, Nguyen, Holly M., Corey, Eva, Liu, Gang, Sprenger, Cynthia C., Plymate, Stephen R., Bogenrieder, Thomas
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!